Merck and Gilead discontinued a Phase 3 lung cancer trial due to lack of statistical significance, while Pfizer initiated a new Phase 1 trial and Roivant Sciences completed enrollment in its Phase 2 PHocus trial for pulmonary hypertension.
Relay Therapeutics reported full-year 2025 revenue of $15.36 million and a narrowed net loss of $276.48 million, while securing FDA Breakthrough Therapy designation for lead asset zovegalisib. The company filed a $96.18 million shelf registration.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05101096 |
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
